FBR Capital Starts Acceleron Pharma (XLRN) at Outperform
Tweet Send to a Friend
FBR Capital initiates coverage on Acceleron Pharma (NASDAQ: XLRN) with a Outperform rating and a price target of $47.00.Analyst Andrew ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE